HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Penederm Avita

This article was originally published in The Rose Sheet

Executive Summary

Penederm Avita: Firm submits to FDA July 16 results from a three-month, 675-patient clinical study showing "statistically significant efficacy at the 95% confidence level" for its anti-acne retinoic acid gel treatment Avita. The study compared Avita to J&J's Retin-A and placebo in four efficacy parameters -- total lesions, inflammatory lesions, noninflammatory lesions and global assessment. Penederm is submitting the results as an amendment to its NDA for Avita after receiving a "non-approvability" letter from FDA for the prescription acne drug. The agency requested additional data on the noninflammatory lesion endpoint, stating that results from Penederm's second clinical study did not replicate those from the first study. The Foster, Calif.-based company said that the results from the third study "address...the clinical issue raised" in FDA's action letter. A second action letter regarding the cream formulation of Avita stated that approval of that product is dependent on approval of the gel version...

You may also be interested in...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts